We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

IV Cocaine Abuse: A Laboratory Model - 1

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000212
First Posted: September 21, 1999
Last Update Posted: August 31, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
National Institute on Drug Abuse (NIDA)
Columbia University
Information provided by (Responsible Party):
New York State Psychiatric Institute
  Purpose
The purpose of this study is to evaluate the effects of desipramine DMI maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving.

Condition Intervention Phase
Cocaine-Related Disorders Drug: Desipramine Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: IV Cocaine Abuse: A Laboratory Model

Resource links provided by NLM:


Further study details as provided by New York State Psychiatric Institute:

Primary Outcome Measures:
  • Amount cocaine self-administered
  • Direct cocaine effects (cardiovascular, subjective
  • Interaction of cocaine and DMI on cardio measures
  • Interaction of cocaine/DMI on coc's subjective
  • Effects of DMI on cocaine craving
  • Drug use during outpatient DMI maintenance

Estimated Enrollment: 0
Study Start Date: July 1987
Study Completion Date: July 1988
Primary Completion Date: July 1988 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000212


Locations
United States, New York
Columbia University
New York, New York, United States, 10023
Sponsors and Collaborators
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)
Columbia University
Investigators
Principal Investigator: Richard Foltin, Ph.D. Columbia University
  More Information

Publications:
Responsible Party: New York State Psychiatric Institute
ClinicalTrials.gov Identifier: NCT00000212     History of Changes
Other Study ID Numbers: NIDA-06234-1
R01DA006234 ( U.S. NIH Grant/Contract )
R01-06234-1
First Submitted: September 20, 1999
First Posted: September 21, 1999
Last Update Posted: August 31, 2015
Last Verified: December 2012

Keywords provided by New York State Psychiatric Institute:
crack cocaine

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Cocaine
Desipramine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Antidepressive Agents, Tricyclic
Antidepressive Agents
Psychotropic Drugs
Enzyme Inhibitors
Adrenergic Uptake Inhibitors
Adrenergic Agents